Alongside the successful application of generics, there is a demand for new treatment methods and substances in the various fields of diseases in order to combat illnesses better.

HAEMATO PHARM AG, a subsidiary, does import branded and patent protected innovative medicines in order to complement the offer of generic products. The MPH group buys original branded products of the various multinational pharma companies in different european countries at competitive prices. By doing so these innovative new pharmaceuticals can be offered in Germany at a low price and contribute to keeping the cost of healthcare in Germany stable. The drug import industry is advocated by german politics.

The product portfolio contains about 500 pharmaceutical products.